Akums Drugs & Pharmaceuticals

What Akums Drugs & Pharmaceuticals does

Akums Drugs & Pharmaceuticals Limited, founded in 2004 by Sandeep Jain and Sanjeev Jain, is India's largest Contract Development and Manufacturing Organization (CDMO), holding an estimated 30% market share in the domestic CDMO sector per Frost & Sullivan's FY2023 assessment. The company operates 15+ state-of-the-art manufacturing facilities with cumulative annual production capacity exceeding 50 billion units across 4,100+ commercialized formulations spanning oral solids, injectables, sterile preparations, soft gels, liquid orals, topicals, hormonal, dermatology, and nutraceutical products. Akums serves 1,500+ pharmaceutical clients globally through an enterprise B2B model, including major Indian pharmaceutical companies (Sun Pharma, Dr. Reddy's, Cipla, Lupin, Glenmark) and multinationals (Sanofi, GSK, Novartis, Sandoz, Abbott), with wholly-owned subsidiary Unosource Pharma distributing branded formulations across 65+ countries.

The company's underlying technology platform centers on DSIR-recognized R&D with 400+ scientists and NABL-accredited laboratories, supported by advanced formulation capabilities including lyophilisation, liposomal, and nano-particulate drug delivery systems. Manufacturing operations comply with 25+ international regulatory certifications including EU GMP, UK MHRA, USFDA, WHO-GMP, Brazil ANVISA, Japan PMDA, PIC/S, and EDQM. Backward integration is achieved through in-house API manufacturing at Derabassi and Lalru facilities. The company is publicly listed on Indian stock exchanges (BSE: 544222) following its August 2024 IPO that raised approximately Rs. 1,875 crore (~$225M).

Revenue is generated through three primary streams: contract manufacturing fees from CDMO services (negotiated on a per-project basis with multi-year contracts), international branded formulations sales through Unosource Pharma (one-time licensing and product registration model), and API manufacturing (both internal use and third-party supply). Pricing is custom-negotiated based on formulation complexity, volume, and regulatory requirements with no publicly disclosed standard pricing tiers. The customer base spans domestic pharmaceutical companies seeking cost-effective manufacturing capacity and international/export clients requiring EU GMP and other regulated-market compliance. As of FY26, Akums reported operating revenue of Rs. 4,359 crore with adjusted PAT of Rs. 276 crore (27.3% YoY growth) and employs over 18,010 people across permanent and worker categories.

Name

Akums Drugs & Pharmaceuticals

Legal name

Akums Drugs & Pharmaceuticals Ltd.

Website

https://akums.in

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Akums Drugs & Pharmaceuticals is India's largest CDMO with 30% domestic market share, operating 15+ manufacturing facilities producing 50+ billion units annually across 4,100+ formulations for 1,500+ pharmaceutical clients worldwide.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Small-Molecule API & Intermediates CDMO (HLAGABAA)

Keywords

• Pharmaceutical contract manufacturing
• API manufacturing
• Pharmaceutical CDMO
• Third-party manufacturing
• Formulation development

Headquarters

HQ city

New Delhi

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. CDMO Services (Contract Manufacturing): Contract development and manufacturing services for domestic and international pharmaceutical companies. Revenue generated through manufacturing fees, formulation development charges, and long-term supply agreements with 1500+ clients.
2. International Branded Formulations: Marketing and sale of own branded pharmaceutical products through subsidiary Unosource Pharma in 65+ countries. Revenue from product registrations and commercial sales.
3. API Manufacturing: Active Pharmaceutical Ingredient manufacturing for internal use and external supply, providing backward integration for formulations business.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Akums Drugs & Pharmaceuticals is India's largest Contract Development and Manufacturing Organization (CDMO) with 30% market share in domestic CDMO. The company provides end-to-end pharmaceutical manufacturing services including formulation development, technology transfer, regulatory support, and large-scale commercial manufacturing across oral solids, injectables, sterile preparations, liquid orals, topicals, hormonal, and dermatology products through 15+ manufacturing facilities with 50+ billion units annual capacity. It also offers API manufacturing, nutraceutical/ayurvedic manufacturing, and cosmetics/derma manufacturing, supported by DSIR-approved R&D and NABL-accredited labs.

Product overview

Akums Drugs & Pharmaceuticals is India's largest Contract Development and Manufacturing Organization (CDMO) with 30% market share in the domestic CDMO sector. The company operates as a unified platform offering end-to-end pharmaceutical manufacturing services through its core divisions: Pharmaceutical Contract Manufacturing (tablets, capsules, injectables, soft gels, syrups, topicals), API Manufacturing, Nutraceutical & Ayurvedic Manufacturing, and Cosmetics & Dermatology Manufacturing. The company also operates through its subsidiary Unsource Pharma for international branded formulations exports. Akums collaborates with 1,500+ pharmaceutical companies, manufacturing over 4,100 commercialized formulations across 15+ state-of-the-art manufacturing facilities with a combined annual production capacity exceeding 50 billion units.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Contract Manufacturing End-to-end CDMO services for formulation development, technology transfer, and large-scale commercial manufacturing of pharmaceutical products including tablets, capsules, injectables, soft gels, syrups, and topicals. Serves 1,500+ domestic and international pharmaceutical clients.
• API Manufacturing Active Pharmaceutical Ingredient manufacturing services with backward integration for the formulations business and external supply. Operates dedicated API manufacturing units meeting international regulatory standards.
• Nutraceutical & Ayurvedic Manufacturing Contract manufacturing services for nutraceutical products combining science and natural ingredients, including general wellness, beauty nutrition, sports nutrition, and women's health supplements. AYUSH GMP certified.
• Cosmetics & Dermatology Manufacturing Innovative cosmetics and derma manufacturing services providing premium skincare solutions, including gel and cream formulations. Supports derma and cosmetic brand development for health and wellness brands.
• Unosource Pharma (International Branded Formulations) Wholly-owned subsidiary handling international branded formulations exports with over 1,200 product registrations across 65+ countries, including regulated markets (EU, UK) and emerging markets in Africa, Southeast Asia, and Latin America.

Quantifiable outcome

• Q4 FY26: 9.7% YoY revenue growth, 61.6% EBITDA growth, PAT more than doubled
• +4 more outcomes

Named customers16 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Triple Hair GroupcoreStrategic or Co-development Partner · 14 May 2026Clinical partnership for Phase III trial of TH07 topical prescription treatment for male androgenic alopecia. Akums serving as clinical manufacturing partner in India for 500-patient trial, part of harmonized international Phase III program totaling ~920 patients.
• CaregencoreStrategic or Co-development Partner · 1 January 2025Partnership with South Korean biotech firm Caregen to launch specialized cosmeceuticals in India. Combines Caregen's biotech expertise with Akums' manufacturing capabilities for innovative derma and cosmetic product development.
• European Pharmaceutical CompanycoreStrategic or Co-development Partner · 1 December 2024Entered €200 million partnership to manufacture oral liquid formulations for the European market starting in 2027, marking significant expansion into regulated European markets.

Scale indicators13 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Syngene International: India-based CRDMO (Contract Research, Development and Manufacturing Organization) offering integrated drug discovery, development, and manufacturing services. Direct competitor in Indian pharma CDMO space with strong international client base.
• Piramal Pharma Solutions: Global CDMO offering drug substance and drug product development and manufacturing services across multiple dosage forms. Directly competes with Akums in contract manufacturing for global pharmaceutical clients.
• Divi's Laboratories: Indian pharmaceutical company with significant API manufacturing and custom synthesis services. Direct competitor in API and intermediates CDMO segment with backward integration similar to Akums.
• Jubilant Pharmova: Indian pharma services company offering contract manufacturing, drug discovery, and radiopharmacy services. Competes with Akums in CDMO segment and shares the regulated market expansion strategy.
• Sai Life Sciences: India-based CRDMO offering drug discovery, development, and manufacturing services. Directly comparable as an emerging Indian CDMO with similar customer base of global pharmaceutical companies.

Broad incumbents

• WuXi AppTec: Global leader in pharmaceutical CDMO and CRO services with comprehensive capabilities from discovery to commercial manufacturing. Significantly larger scale but operates in same CDMO category.
• Catalent: Global CDMO specializing in advanced delivery technologies and sterile manufacturing. Broader incumbent competing for high-value international contract manufacturing work.
• Lonza Group: Swiss-based global CDMO leader offering services across small molecules, biologics, and cell & gene therapies. Major international competitor in regulated market CDMO.
• Aurobindo Pharma: Large Indian pharmaceutical manufacturer with significant API and formulation capabilities. While primarily a generics company, competes with Akums for CDMO partnerships and contract manufacturing.

Regional players

• Laurus Labs: Indian pharmaceutical company with API, formulation, and CDMO businesses. Comparable in scale and Indian market focus, serving similar global pharma clients with contract manufacturing services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/akums
• Xx.com/AkumsOfficial
• Facebookfacebook.com/AkumsDrugsPharmaceuticalsLtd

Compliance23 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Akums Drugs & Pharmaceuticals